Finding new treatments for bile duct cancer
Identifying therapeutic options for intrahepatic cholangiocarcinoma
This study is looking at bile duct cancer to find specific markers in the genes and proteins that could help create better treatments for patients, making it easier to fight this tough disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11053521 on NIH RePORTER |
What this research studies
This research focuses on intrahepatic cholangiocarcinoma (ICC), a type of bile duct cancer with a very low survival rate. The team is investigating the genetic and molecular characteristics of ICC to identify specific biomarkers that can help tailor treatments for patients. By studying how certain proteins and genes interact in cancer cells, they aim to develop targeted therapies that could improve patient outcomes. The research involves analyzing patient samples and using advanced genetic techniques to understand the disease better.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with intrahepatic cholangiocarcinoma.
Not a fit: Patients with other types of cancer or those without a diagnosis of intrahepatic cholangiocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective, personalized treatment options for patients with bile duct cancer.
How similar studies have performed: Other research has shown promise in identifying targeted therapies for various cancers, suggesting that this approach could also be effective for intrahepatic cholangiocarcinoma.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Ko, Sungjin — University of Pittsburgh at Pittsburgh
- Study coordinator: Ko, Sungjin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.